drugset / Trial / NCT05112991
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Non-randomizedFactorialOpen-labelTreatment
Summary
This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.
Timeline
- Start
- 2022-03-04
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Envafolimab | Monoclonal antibody | 400 mg | — |
| Subject | Lenvatinib | Small molecule | 20 mg | Oral |